ANNUAL REPORT 2021
LUNDBECK
ANNUAL REPORT 2021
= CONTENTS
IQVIA
19/111
INTERNATIONAL MARKETS
Revenue from International Markets, which comprises all
Lundbeck's markets outside of Europe and North America,
reached DKK 4,155 million in 2021. The growth of 6% in local
currencies was driven by RexultiⓇ/RxultiⓇ and
BrintellixⓇ/TrintellixⓇ. The biggest markets are China, Japan,
South Korea, Australia and Brazil. China and Japan constitute
approximately 40% of the regional revenue. The strategic
brands increased by 27% in local currencies and reached DKK
1,067 million or 26% of sales. In local currencies, all products
grew compared to last year. Other pharmaceuticals declined by
5%.
International Markets constituted 26% of total revenue
(excluding effects from hedging and Other revenue), which is a
small decrease from last year.
Abilify MaintenaⓇ reached DKK 226 million in revenue
representing a growth of 8% (4% in local currencies). Sales
mainly derived from Australia where Abilify MaintenaⓇ shows
robust sales performance.
BrintellixⓇ/TrintellixⓇ reached DKK 739 million in revenue or an
increase of 32% in local currencies. BrintellixⓇ/TrintellixⓇ
realized solid growth across several markets including China
and Japan. China, Brazil, Japan, South Korea and Mexico are
the largest markets for BrintellixⓇ/TrintellixⓇ in the region. In
China, BrintellixⓇ has a value share of 1.4% by October 2021*.
In Japan, TrintellixⓇ is showing very strong momentum and has
reached a volume market share of 5.5% by December 2021*.
RexultiⓇ/RxultiⓇ reached DKK 99 million in sales and grew by
55% in local currencies. In International Markets, the product
has its highest sales in Australia followed by Brazil.
VyeptiⓇ received approval in the U.A.E. in December 2020 and
in Kuwait in May 2021. In June 2021, The Australian
Therapeutic Goods Administration (TGA) approved VyeptiⓇ for
the preventive treatment of migraine in adults with a very strong
label. VyeptiⓇ was introduced in the U.A.E. towards the end of
September 2021.
CipralexⓇ/LexaproⓇ generated revenue of DKK 1,699 million
representing a growth of 4% in local currencies. Japan, China,
South Korea, Brazil and Hong Kong are the largest markets for
CipralexⓇ/LexaproⓇ in the region.
Other pharmaceuticals generated revenue of DKK 1,389
million. AzilectⓇ is promoted by Lundbeck in some countries in
Asia. AzilectⓇ generated revenue of DKK 135 million following a
growth of 13%. EbixaⓇ generated revenue of DKK 397 million,
which is 20% lower compared to 2020 following the inclusion of
EbixaⓇ into Volume-Based Procurement (VBP) in China in the
fourth quarter of 2020.
REVENUE - INTERNATIONAL MARKETS
DKKm
Abilify MaintenaⓇ
BrintellixⓇ/TrintellixⓇ
RexultiⓇ/RxultiⓇ
Strategic brands
CipralexⓇ/LexaproⓇ
Other pharmaceuticals
Total revenue
Growth
2021
2020
Growth
in local
currencies
226
210
8%
4%
739
583
27%
32%
99
65
52%
55%
1,067
858
24%
27%
1,699 1,730 (2%)
1,389 1,469 (5%)
4,155 4,057 2%
4%
(4%)
6%View entire presentation